Literature DB >> 20187228

Inflammation and Parkinson's disease pathogenesis.

Serge Przedborski1.   

Abstract

Inflammation is a neuropathological feature of parkinsonian brains and also in experimental models of the disease. It is believed that activated glial cells, which compose the majority of this inflammatory response contribute to the neurodegenerative process through the production of toxic molecules. Therapeutic strategies geared toward reducing inflammation and inhibiting the production of these glial-derived toxic molecules may be a promising neuroprotective strategy for the treatment of Parkinson's disease and related conditions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187228     DOI: 10.1002/mds.22638

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  33 in total

1.  Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?

Authors:  Mariza Bortolanza; Fernando E Padovan-Neto; Roberta Cavalcanti-Kiwiatkoski; Maurício Dos Santos-Pereira; Miso Mitkovski; Rita Raisman-Vozari; Elaine Del-Bel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-05       Impact factor: 6.237

2.  Interferon Gamma potentiates the injury caused by MPP(+) on SH-SY5Y cells, which is attenuated by the nitric oxide synthases inhibition.

Authors:  Simoneide S Titze-de-Almeida; Cátia Faria Lustosa; Camila Hillesheim Horst; Elaine Del Bel; Ricardo Titze-de-Almeida
Journal:  Neurochem Res       Date:  2014-10-09       Impact factor: 3.996

Review 3.  Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.

Authors:  Brianne Magouirk Bettcher; Joel H Kramer
Journal:  Neurocase       Date:  2012-04-19       Impact factor: 0.881

4.  HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration.

Authors:  Hui-Ming Gao; Hui Zhou; Feng Zhang; Belinda C Wilson; Wayneho Kam; Jau-Shyong Hong
Journal:  J Neurosci       Date:  2011-01-19       Impact factor: 6.167

5.  Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat.

Authors:  Daniel R van Bregt; Theresa Currier Thomas; Jason M Hinzman; Tuoxin Cao; Mei Liu; Guoying Bing; Greg A Gerhardt; James R Pauly; Jonathan Lifshitz
Journal:  Exp Neurol       Date:  2011-12-09       Impact factor: 5.330

6.  Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.

Authors:  Melanie B Watson; Franziska Richter; Soo Kyung Lee; Lauryn Gabby; Jennifer Wu; Eliezer Masliah; Rita B Effros; Marie-Françoise Chesselet
Journal:  Exp Neurol       Date:  2012-06-27       Impact factor: 5.330

7.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.

Authors:  Valentín Cóppola-Segovia; Clarissa Cavarsan; Flavia G Maia; Anete C Ferraz; Lia S Nakao; Marcelo Ms Lima; Silvio M Zanata
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

8.  6-Shogaol, an active compound of ginger, protects dopaminergic neurons in Parkinson's disease models via anti-neuroinflammation.

Authors:  Gunhyuk Park; Hyo Geun Kim; Mi Sun Ju; Sang Keun Ha; Yongkon Park; Sun Yeou Kim; Myung Sook Oh
Journal:  Acta Pharmacol Sin       Date:  2013-07-01       Impact factor: 6.150

9.  Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast.

Authors:  Hilary Grosso; Jong-Min Woo; Kang-Woo Lee; Joo-Young Im; Eliezer Masliah; Eunsung Junn; M Maral Mouradian
Journal:  FASEB J       Date:  2014-06-26       Impact factor: 5.191

Review 10.  Prostanoid receptor EP2 as a therapeutic target.

Authors:  Thota Ganesh
Journal:  J Med Chem       Date:  2013-12-04       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.